Comparing lamivudine plus dolutegravir and bictegravir/emtricitabine/ tenofovir alafenamide in antiretroviral therapynaive HIV-infected patients: preliminary results from clinical practice

被引：0
|
作者：
Long, H. [1 ]
机构：
[1] Guiyang Publ Hlth Clin Ctr, Guiyang, Peoples R China
来源：
HIV MEDICINE | 2023年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
406
引用
收藏
页码：105 / 106
页数：2
相关论文
共 50 条
  • [41] Switching to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) plus darunavir/cobicistat (DRV/c) in heavily antiretroviral-experienced, virologically suppressed HIV-infected adults receiving complex regimens
    Podzamczer, D.
    Imaz, A.
    Lopez Lirola, A.
    Knobel, H.
    Masia, M.
    Berenguer, J.
    Hernandez, C.
    Lagarde, M.
    Gutierrez, A.
    Curran, A.
    Morano, L.
    Montero-Alonso, M.
    Troya, J.
    Rigo, R.
    Casadella, M.
    Navarro-Alcaraz, A.
    Rivero Roman, A.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2022, 25 : 81 - 82
  • [42] Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide in clinical practice: pooled 12-month results from the global BICSTaR study
    Spinner, C.
    Stoehr, A.
    Wong, A.
    de Wet, J.
    Zeggagh, J.
    Hocqueloux, L.
    van Welzen, B.
    Heinzkill, M.
    Sahali, S.
    Cornejo, A. Torres
    Ramroth, H.
    Haubrich, R.
    Thorpe, D.
    Kim, C.
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2020, 23 : 50 - 51
  • [43] Comparing the long-term effectiveness and safety of dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate as first-line regimens: a real life multicentre cohort
    Ciccullo, Arturo
    Baldin, Gianmaria
    Cervo, Adriana
    Moschese, Davide
    Lagi, Filippo
    Cossu, Maria Vittoria
    Grimaldi, Alessandro
    Giacomelli, Andrea
    Rusconi, Stefano
    Sterrantino, Gaetana
    Borghetti, Alberto
    Antinori, Spinello
    Mussini, Cristina
    Di Giambenedetto, Simona
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2024, 80 (01) : 175 - 177
  • [44] Changes in Serum Inflammatory Markers in Antiretroviral Therapy-Naive HIV-Infected Patients Starting Dolutegravir/Lamivudine or Dolutegravir/Lamivudine/Abacavir
    Calza, Leonardo
    Legnani, Giorgio
    Fulgaro, Ciro
    Verucchi, Gabriella
    Bon, Isabella
    Lazzarotto, Tiziana
    Viale, Pierluigi
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2022, 89 (03) : E30 - E32
  • [45] Effectiveness, safety and tolerability of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in HIV-1 infected adult patients in routine clinical practice-6 months results of the BICSTaR cohort
    Esser, S.
    Jessen, H.
    Schneider, J.
    Schellberg, S.
    Stellbrink, H-J
    Waizmann, M.
    Hillenbrand, H.
    Bilbao, P.
    Schreiber, S.
    Thorpe, D.
    Ramroth, H.
    Haubrich, R.
    Heinzkill, M.
    HIV MEDICINE, 2019, 20 : 61 - 61
  • [46] Switch to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) among vulnerable HIV-infected individuals: evidence for long-term efficacy
    Truong, David
    Yi, Shana
    Wiesmann, Christina
    Conway, Brian
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 181 - 181
  • [47] Dolutegravir/lamivudine versus bictegravir/emtricitabine/tenofovir alafenamide fumarate: Real-world Assessment of weight Gain in naive people living with HIV of Asian OrigiN (DRAGON study)
    Chen, Jang-Pin
    Chen, Tsung-Chia
    Hsih, Wen-Hsin
    Tsai, Mao-Song
    Yang, Chia-Jui
    Cheng, Shu-Hsing
    Lin, Yi-Chun
    Ma, Ping
    Zhao, Qingxia
    Zou, Meiyin
    Wu, Yi-Wen
    Huang, Miao-Hui
    Sheng, Wang-Huei
    Cheng, Chien-Yu
    JOURNAL OF THE INTERNATIONAL AIDS SOCIETY, 2024, 27 : 267 - 268
  • [48] Changes in Serum Markers of Inflammation and Endothelial Activation in HIV-Infected Antiretroviral Naive Patients Starting A Treatment with Abacavir-Lamivudine or Tenofovir-Emtricitabine Plus Efavirenz
    Calza, Leonardo
    Magistrelli, Eleonora
    Danese, Ilaria
    Colangeli, Vincenzo
    Borderi, Marco
    Bon, Isabella
    Re, Maria Carla
    Mancini, Rita
    Conti, Matteo
    Motta, Roberto
    Viale, Pierluigi
    CURRENT HIV RESEARCH, 2016, 14 (01) : 61 - 70
  • [49] Treatment persistence of bictegravir/emtricitabine/tenofovir alafenamide and efavirenz + lamivudine + tenofovir disoproxil among HIV-1 patients newly starting treatment in Hunan Province in China
    Cao Jing
    Tang Wei
    Wang Ning
    Zheng Fang
    Xiao Gang
    Wang Xingzhi
    Zhou Guoqiang
    Wang Min
    BMC Infectious Diseases, 23
  • [50] Comparing effectiveness and tolerability of emtricitabine/tenofovir alafenamide (F/TAF) with emtricitabine/tenofovir disoproxil fumarate (F/TDF) in HIV-1 infected adult patients in routine clinical practice: a cross cohort analysis
    Esser, S.
    Stellbrink, H-J
    Heiken, H.
    Meynard, J-L
    Thorpe, D.
    Schreiber, S.
    Heinzkill, M.
    Sahali, S.
    Ramroth, H.
    Haubrich, R.
    HIV MEDICINE, 2019, 20 : 67 - 68
12345